AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06247306 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ScanSTRESS fMRI-paradigm (Streit et al., 2014)
Description: The task is conducted within the MRI scanner and consists of two runs each lasting 11:20 mins., employs a block design and has two different conditions (performance, relaxation), as well as two different task within each condition. Participants undergo the following 2 tasks during the performance condition under time pressure: 1) serial subtraction, 2) a figure matching task. During the performance condition, all participants receive feedback (work faster, mistake, too slow) and are reprimanded concerning their performance. Two investigators in white coats observe the participants with critical facial expression, which is projected to participants through live-video feed during the tasks. The relaxation condition includes easy versions of arithmetic and figure matching task without time constrains or any type feedback on their performance. Performance and relaxation phases are appear in alternating order.
Study NCT06247306 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: real-time fMRI neurofeedback
Description: Two real-time fMRI neurofeedback sessions of 9:30 minutes each are conducted. During these sessions, the participants are instructed to regulate a feedback signal from the ACC. Participants are assigned to either the experimental or Yoke-control group through an automated double-blind procedure. In the neurofeedback sessions, participants in the experimental group receive a feedback signal indicating their current ACC activation. Participants in the control group receive the recorded feedback signal from another participant. The neurofeedback sessions follow a block structure with alternating feedback and rest periods.~Before, between, and after the two sections of the fMRI examination, subjective stress levels and alcohol craving are assessed, and saliva samples are collected for cortisol level determination.
Study NCT06247306 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: real-time fMRI neurofeedback
Description: Two real-time fMRI neurofeedback sessions of 9:30 minutes each are conducted. During these sessions, the participants are instructed to regulate a feedback signal from the ACC. Participants are assigned to either the experimental or Yoke-control group through an automated double-blind procedure. In the neurofeedback sessions, participants in the experimental group receive a feedback signal indicating their current ACC activation. Participants in the control group receive the recorded feedback signal from another participant. The neurofeedback sessions follow a block structure with alternating feedback and rest periods.~Before, between, and after the two sections of the fMRI examination, subjective stress levels and alcohol craving are assessed, and saliva samples are collected for cortisol level determination.
Study NCT05797766 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fluid Distribution Timetable
Description: a scheduled distribution of predetermined amounts of fluid intake daily depicted in a 5x6 table. The timetable has three major columns. The first column has six-time points of a day with a four-hour interval. The second column, which was divided into four sub-columns, reflects the percentage of fluid allotment for food, activities, medication, and thirst encounters. The percentage of fluid allocation was computed based on the patient's prescribed fluid restriction, usual time of food intake per day, usual level of activity, time of medication intake, and common time they encounter thirst for a day. The third column indicates the converted percentage of fluid allotment into milliliters.
Study NCT04893668 — intervention group
Intervention type: OTHER
Intervention: Depression
Description: Any participants who develop depression symptoms according to DSM 5 criteria
Study NCT04893668 — intervention group
Intervention type: OTHER
Intervention: Anxiety
Description: Any participants who develop anxiety symptoms according to DSM 5 criteria
Study NCT04824261 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clotrimazol solution 1%
Description: 50 otomycosis randomized patients will receive Clotrimazol solution 1% The treatment will be locally applied for at least 2 weeks. All the patients will be followed up after the 1st week, 2nd week and after 1 month.
Study NCT04824261 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 4%boric acid in distilled water
Description: 50 otomycosis randomized patients will receive 4%boric acid in distilled water The treatment will be locally applied for at least 2 weeks. All the patients will be followed up after the 1st week, 2nd week and after 1 month.
Study NCT06493019 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Chemoradiation Pembrolizumab 200mg IV
Study NCT06493019 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel 50 mg/m\^2 IV
Study NCT06493019 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin AUC 2 IV
Study NCT06493019 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Description: Delivered as per institutional standards
Study NCT06493019 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Maintenance Pembrolizumab 400mg IV
Study NCT06562283 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Thumb test
Description: Thumb adduction test consisting of intermittent, repetitive isometric contractions lasting 5 seconds at incremental percentages of maximum force.
Study NCT06562283 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Grip test
Description: Muscle contraction gripping test, consisting of intermittent, repetitive isometric contractions lasting 5 seconds at incremental percentages of maximum force.
Study NCT06562283 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quadriceps Intermittent Fatigue test (QIF test))
Description: Quadriceps muscle contraction test consisting of intermittent, repetitive isometric contractions lasting 5 seconds at incremental percentages of maximum force.
Study NCT05908097 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Reality Avatar Intervention
Description: In the Virtual Reality Avatar Intervention experience, participants will see an avatar resembling themselves in a park setting. The Virtual Reality Empty Park experience is a habituation experience that does not contain avatars.
Study NCT05908097 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Virtual Reality Empty Park
Description: The Virtual Reality Empty Park experience is a habituation experience that does not contain avatars.
Study NCT05908097 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Reality Empty Park
Description: The Virtual Reality Empty Park experience is a habituation experience that does not contain avatars.
Study NCT05264363 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VIPUN Gastric Monitoring System prototype
Description: The Investigational Medical Device (IMD) is used simultaneously with the reference device (solid state high-resolution manometry) to record gastric intraluminal pressure for approximately 2.5 hours.
Study NCT06482658 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transrectal perilesional/regional systematic biopsy (PB/RSB)
Description: The biopsy procedure was conducted by a highly skilled and experienced urologist who specializes in performing prostate biopsies. Prophylactic antibiotics were routinely used both before and one day prior to scheduled surgery. Each patient was placed in the left lateral position. The ultrasound equipment used included a color Doppler ultrasound diagnostic instrument (Hitachi HiVision, Philips Epiq 7), transrectal probes, and corresponding puncture needle guns. Color Doppler examination was performed from the base to the apex. For each predefined mpMRI suspicious lesion, urologists obtained nine cores at 5-mm intervals within and around the region of interest (penumbra) through transrectal prostate biopsy. The location of these nine cores depended on the shape and location of the suspicious lesion.
Study NCT04080934 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Swimming
Description: Patients will participate in 8 weeks of the swimming program, which involves three weekly swimming sessions of 30 minutes minimum.
Study NCT04281498 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: Patients who are on ruxolitinib will continue their current dose. Patients who are not on ruxolitinib will receive ruxolitinib dosing based on platelet count
Study NCT04281498 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enasidenib
Description: 50mg -100mg daily
Study NCT05640648 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: User-Centered Implementation Strategy
Description: 1. 4 participant-facing components: 1a) TB education pamphlet helps index TB persons disclose the need for household screening to contacts. 1b) Contact identification algorithm helps CHWs and index TB persons accurately enumerate contacts. 1c) Sputum collection video instructs contacts to expectorate good-quality sputum. 1d) Community Health Riders transport CHWs, index persons with TB, and contacts by motorcycle taxi, and collect and transport sputum.~2. 3 community health-worker-facing components: a) Weekly CHW meetings create communities of practice (CoP), professionals organized for peer support and systematic learning. Meetings involve problem solving, review of audit and feedback reports, and didactics on TB care, among other activities. 2b) Audit and feedback reports on contact investigation performance indicators weekly (individual CHW) and monthly (health facility). 2c) A group-chat application facilitates peer support among CHWs.
Study NCT05640648 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Implementation Strategy
Description: Once an eligible TB patient agrees to participate, CHWs will visit the patient to assess the eligibility of close contacts to participate. For eligible contacts who agree to participate, the CHW will perform TB symptom screening and arrange subsequent microbiologic, clinical, and/or radiographic evaluation. Those screening TB symptom-positive will be asked to expectorate a sputum sample, unless under age 5. If under age 5 or unable to produce sputum, contacts will be referred to the health centre for evaluation. A CHW will transport sputum samples to the health-centre laboratory for microbiologic evaluation and later report the test results back to the contact. During the standard implementation strategy period, CHWs at all sites will receive the standard TB program training on TB contact investigation and supportive supervision from the on-site National TB Program focal person.
Study NCT05841849 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aprepitant
Description: oral aprepitant capsules 125mg for D1 before chemotherapy, 80mg for D2 and D3
Study NCT05841849 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Palonosetron
Description: oral palonosetron 0.5mg for D1 before chemotherapy; intravenous palonosetron 0.25mg for D1 before chemotherapy;
Study NCT05841849 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palonosetron
Description: oral palonosetron 0.5mg for D1 before chemotherapy; intravenous palonosetron 0.25mg for D1 before chemotherapy;
Study NCT05841849 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fosaprepitant
Description: intravenous fosaprepitant 150mg for D1 before chemotherapy
Study NCT06482658 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Combination of transrectal systematic biopsy and targeted biopsy
Description: The biopsy procedure was conducted by a highly skilled and experienced urologist who specializes in performing prostate biopsies. Prophylactic antibiotics were routinely used both before and one day prior to scheduled surgery. Each patient was placed in the left lateral position. The ultrasound equipment used included a color Doppler ultrasound diagnostic instrument (Hitachi HiVision, Philips Epiq 7), transrectal probes, and corresponding puncture needle guns. Color Doppler examination was performed from the base to the apex. Three to five transrectal targeted biopsies from the lesion were performed within and around the predefined mpMRI suspicious lesion, followed by fore-zone 12-core transrectal prostate biopsy.
Study NCT06058663 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Angiography
Description: Undergo mapping angiography
Study NCT06058663 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo biopsy
Study NCT06058663 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study NCT06058663 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT
Study NCT06058663 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Given IV
Study NCT06058663 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study NCT06058663 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET/CT
Study NCT06058663 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tremelimumab
Description: Given IV
Study NCT06058663 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Yttrium-90 Microsphere Radioembolization
Description: Receive transarterial Y90 radioembolization
Study NCT05803343 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Regulating Together-Canine
Description: RT-C is an animal assisted, intensive outpatient group intervention for children with autism spectrum disorder and emotion dysregulation. RT-C meets for 1.5 hours, twice weekly for five weeks with concurrent youth and caregiver groups. The children progress through skills including relaxation training, arousal ratings, problem size, mindfulness, problem solving, and cognitive flexibility. The caregivers learn crisis management, reward systems, and coaching strategies for topics taught to the children. Homework is utilized to reinforce use of skills outside the group. The canines are present throughout as both a calming presence and teaching assistant. Children will be able to interact with the dog when practicing relaxation at the beginning of each session and throughout the session. Additionally, the dog will help to emphasize certain curriculum concepts.
Study NCT05803343 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Regulating Together-Standard
Description: RT-S an established, intensive outpatient group intervention for children with autism spectrum disorder and emotion dysregulation. It engages both caregivers and children and utilizes evidence-based intervention techniques including cognitive behavioral therapy (CBT), visuals, reinforcements, and scaffolding, and newer interventions such as mindfulness and acceptance-based therapy.
Study NCT05161936 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lumasiran
Description: Lumasiran will be administered by SC injection.
Study NCT05161936 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered by SC injection.
Study NCT05220995 — intervention group
Intervention type: GENETIC
Intervention: protocol
Description: ovarian stimulation protocols on euploid rates were compared.
Study NCT05898373 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vedicitumomab (Edisil, RC48）
Description: intravenously for 6-8 cycles before surgery and postoperative radiotherapy, followed by Treatment with injectable recombinant humanized anti-HER2 monoclonal antibody-MMAE coupling agent vedicitumomab (Edisil, RC48) until 1 year or disease progression or intolerable toxicity in locally advanced patients , and until disease progression or intolerable toxicity in metastatic patients .
Study NCT05898373 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vedicitumomab in combination with pyrrolizidine
Description: vedicitumomab in combination with pyrrolizidine
Study NCT05898373 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RC48 in combination with a platinum-based chemotherapeutic agent
Description: RC48 in combination with a platinum-based chemotherapeutic agent
Study NCT05898373 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RC48 in combination with teraplizumab
Description: RC48 in combination with teraplizumab
Study NCT05357794 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin
Description: Given by Vein (IV)
Study NCT06307600 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RD06-03 cell injection
Description: The patients in this intervention will use RD06-03 cell injection with 3 dose dose 1: 1×10\^5 CAR+ T Cells/kg dose 2: 3×10\^5 CAR+ T Cells/kg dose 3: 5×10\^5 CAR+ T Cells/kg Dosage form: IV injection Frequency of administration：1 time
Study NCT06407440 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: control
Description: There will be no interference ergonomics training
Study NCT06407440 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercise
Description: upper extremity strengthening exercises upper extremity stretching exercises ergonomics training posture training relaxation exercises
Study NCT05219812 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY2395840
Description: Tablet, intake orally.
Study NCT05219812 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for BAY2395840
Description: Tablet, intake orally.
Study NCT05350917 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Tislelizumab: 200 mg, d1, intravenous infusion (ivgtt) administration, 21 days as a cycle.~DisitamabVedotin : 2mg/kg, d1, intravenous drip (ivgtt) administration, 21 days as a cycle.~Pyrotinib maleate tablets: 320 mg each time, Qd, orally administered within 30 minutes after breakfast, 21 days as a cycle.~Continuous administration until disease progression, death, toxicity intolerance, withdrawal of informed consent, or other reasons specified in the protocol; for patients who still benefit after comprehensive evaluation after initial disease progression, the investigator may decide whether to continue the treatment with the experimental drug .
Study NCT05552482 — intervention group
Intervention type: OTHER
Intervention: Identification of predictive factors
Description: Evaluation of the following variables : age, sex, body mass index, Diabetes mellitus, vascular disease, hematologic disease, venous thromboembolic disease, antiplatelet or anticoagulant treatments, haemodialysis Catheter Insertion, number of comorbid conditions, Venous diameter, Arterial diameter, AVF type, AVF limb, Anasthesia group
Study NCT06442020 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tadalafil (PDE5i)
Description: Tadalafil at a dose of 5mg/day
Study NCT06442020 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Tadalafil (PDE5i)
Description: Tadalafil at a dose of 5mg/day
Study NCT06486506 — intervention group
Intervention type: OTHER
Intervention: Analysis
Description: Analysis and review of imaging and clinical data
Study NCT04968405 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Catalyst CSR Total Shoulder System
Description: The Catalyst CSR Shoulder System is a bone preserving total shoulder prosthesis designed for use in patients where the humeral head, neck and glenoid vault are of sufficient bone stock and there is an intact or reconstructable rotator cuff. The design requires minimal bone resection, thus giving the patient an alternative to other total shoulder designs where more bone is removed.
Study NCT06121973 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: educational group
Description: Experimental group received online video-supported breastfeeding education in an online classroom for 6-8 people and individual counselling via phone and Whatsapp application when needed for 3 weeks.
Study NCT06446479 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dronabinol Pill
Description: Dronabinol 20 mg
Study NCT06446479 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: placebo
Study NCT06521021 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: AVOID
Description: Behavioral: Home food environment and grocery delivery (AVOID) Participants will receive coaching (Zoom and/or email/text) to modify their home food environment and alter cues to promote healthy food choices~Behavioral: WW Participants assigned to all arms will receive of coaching (Zoom and/or email/text) and commercially-available weight management program focusing on diet, physical activity and mindset skills.
Study NCT06521021 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: RESIST
Description: Behavioral: Inhibitory control training (RESIST) Participants assigned to RESIST will receive coaching (Zoom and/or email/text) and gamified inhibitory control training.~Behavioral: WW Participants assigned to all arms will receive coaching (Zoom and/or email/text) and commercially-available weight management program focusing on diet, physical activity and mindset skills.
Study NCT05421754 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ANNE Sleep
Description: ANNE Sleep system for 1 night with HST followed by 3 nights of ANNE Sleep system alone.
Study NCT06023212 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid
Description: IV drip of 2 bottles of tranexamic acid (2g) before making incision during surgery；~1g tranexamic acid soaked gauze applied to the wound for 5 minintes before suture； patients were administered IV drip of tranexamic acid 3 times (every 8 hours)within 24 hours after surgery.
Study NCT06023212 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: stroke-physiological saline solution (SPSS)
Description: IV drip of 2 bottles of saline before making incision during surgery； saline soaked gauze applied to the wound for 5 minintes before suture； patients were administered IV drip of saline 3 times (every 8 hours)within 24 hours after surgery.